When the Biohaven-owned oral migraine drug Nurtec ODT started steaming ahead in 2021, Eli Lilly sought to blunt the rival’s momentum with a trial designed to show its injectable Emgality works better ...

Eli Lilly LLY announced that the phase IV CHALLENGE-MIG study, evaluating the efficacy and safety of its migraine drug Emgality against Pfizer‘s PFE Nurtec ODT, failed to meet primary endpoint of ...

From June 1, the migraine prevention drug Emgality has been expanded on the Pharmaceutical Benefits Scheme, making it ...

Thousands of Australians living with frequent migraines will now be able to access a treatment many describe as life-changing ...

Two months after a federal judge overturned a $176 million jury verdict against Eli Lilly and Co in a patent infringement lawsuit, the dispute seems to be winding down. Indianapolis-based Lilly and ...

(Reuters) - Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal ...

A federal judge has overturned a $176.5 million jury verdict against Eli Lilly and Co., finding that the Indianapolis-based drugmaker did not infringe on the patents of a competitor in developing a ...

Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.

Teva said Lilly migraine drug infringes its patents on rival drug Court finds Lilly failed to prove that patents lacked valid written description (Reuters) - A Boston federal judge on Monday rejected ...

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...